Effect of NT-proBNP Guided Treatment of Chronic Heart Failure

Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00149422

Enrollment

Unknown

Registered

2005-09-08

Start date

2004-06-30

Completion date

2009-04-30

Last updated

2010-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Congestive

Keywords

NT-proBNP

Brief summary

The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.

Interventions

DEVICENT-proBNP measurements

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Admission because of congestive heart failure * Elevated NT-proBNP levels on admission

Exclusion criteria

* Life-threatening cardiac arrhythmias * Urgent intervention * Severe lung disease * Presence of life threatening disease * Signed informed consent for other study * Mental or physical status not allowing written informed consent. * Unwillingness to give informed consent * Patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)

Design outcomes

Primary

Measure	Time frame
Difference in total number of days alive and outside the hospital between the NT-proBNP guided and the clinical guided group.	minimum of one year

Secondary

Measure	Time frame
Cardiovascular mortality	at least one year
All cause hospitalization	at least one year
Cardiovascular related hospitalization	at least one year
Total number of hospitalizations and mortality	at least one year
All cause mortality	at least one year
Differences in primary and secondary outcome measures among renal function and age subgroups	At least one year
Differences in evidence based heart failure medication prescription after 3, 6 and 12 months	At least one year
Analysis of major endpoints in patients where NT-proBNP levels were at or below the individual target level in at least 75% of all outpatient visits	at least one year
Total number of cardiovascular hospitalizations and mortality	at least one year

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026